GLP-1 Receptor Agonists: Current Understanding and Emerging Therapeutic Horizons
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 30 January 2026 | Viewed by 30
Special Issue Editor
Interests: inflammation; anti-inflammatory drugs; depression; antidepressant drugs; biomarkers; drug delivery systems; in vivo animal models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a cornerstone in the management of type 2 diabetes mellitus, offering significant glycemic control, weight reduction, and cardiovascular benefits. Recent advances have expanded their potential therapeutic applications beyond glycemic regulation, including obesity management, non-alcoholic steatohepatitis (NASH), and neurodegenerative disorders. The molecular mechanisms underlying their pleiotropic effects involve enhanced insulin secretion, delayed gastric emptying, appetite suppression, and anti-inflammatory pathways. Despite substantial progress, key challenges remain regarding long-term safety, patient adherence, and individualized therapy. Future research is focused on optimizing pharmacokinetic profiles, exploring novel delivery systems, and expanding indications through combination therapies and dual- or tri-agonist strategies. GLP-1 receptor agonists thus represent a rapidly evolving therapeutic class with far-reaching implications for metabolic and chronic disease management.
We invite researchers and clinicians to contribute original research and comprehensive reviews that explore cutting-edge approaches to all facets of GLP-1 receptor agonists treatment.
Prof. Dr. Maria Bogdan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GLP-1 receptor agonists
- nanotechnology
- pharmacokinetics
- delivery systems
- advanced therapies
- adherence
- drug repurposing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
